Lenacapavir

A New Era in HIV Prevention with Long-Acting Injections

by

Zimbabwe has started rolling out Lenacapavir, the new long-acting injectable HIV-prevention drug, becoming one of the first countries in the world to do so. Lenacapavir is the first twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV, offering a highly effective, long-acting alternative to daily oral pills. With only two doses per year, experts say it provides … Read more

HIV can develop resistance to lenacapavir, but at a cost to the virus

by

  Since its first approval in 2022, Gilead Sciences’ lenacapavir—a twice-yearly injectable—has come to be a potential game changer for preventing HIV and for treating multidrug-resistant HIV, where it’s used in combination with other antiretrovirals. The drug targets the HIV-1 capsid protein and inhibits viral replication.